The TSA shutdown is grinding airports to a halt. If you're running a biotech supply chain with the same kind of single-point-of-failure risk, the question isn't whether you'll face your own version of this crisis — it's when.

Across the biotech industry, sponsor-CMO friction is one of the most persistent operational challenges. When your CMO underperforms, it's your patients, your timelines, and your regulatory standing on the line. Here's how to have the hard conversation — without torching the relationship.

Most early-stage biotech companies wait too long to build a real supply chain function — and the ones that don't often build the wrong things first. Here's what the right sequencing looks like and the three decisions that matter most in year one.